Silymarin

Compound Class	Silymarin is a flavonolignan complex, not a single molecule — no meaningful single CAS applies
Representative Members	Silybin A and B (~50–70% of the complex), isosilybin, silychristin, silydianin, plus taxifolin
Botanical Source	Silybum marianum (milk thistle; dugdhapathri)
Plant Part(s)	Seed (fruit/achene)
Typical Standardisation	Silymarin by HPLC or spectrophotometry; 80% is the standard commercial grade
Primary Applications	Hepatoprotective formulation; drug-induced liver injury prophylaxis; NAFLD/NASH support
Claim Strength (Overview)	Mixed — Moderate for anti-TB drug-induced liver injury prophylaxis; weak-to-null for viral hepatitis and cirrhosis mortality
Buy from Herbuno	Silymarin 80% Powder (Milk Thistle Extract) | Standardized Silybum marianum → Silybin 30% Powder (Milk Thistle Extract) | Standardized Silybum marianum →

Name origin: Silymarin is a collective name for the flavonolignan complex of Silybum marianum, and this is the first thing a formulator must internalise: it is not a molecule but a defined mixture — principally silybin A and B, isosilybin A and B, silychristin, and silydianin, together with the flavonoid taxifolin. The genus name derives from the Greek silybon, a thistle; marianum from the legend that the white leaf veining came from the Virgin Mary’s milk. Traditional use: Milk thistle has one of the more sharply focused traditional indications in European herbal medicine: liver and biliary complaints. Dioscorides described it, and it appears through the medieval and early modern herbals consistently for jaundice, liver congestion, and "diseases of the liver and spleen" — a traditional targeting that modern pharmacology has largely, though not universally, borne out. Research trajectory: Silymarin has been extensively studied, and the honest summary is that the evidence is considerably more mixed than its commercial ubiquity suggests. It has performed well in some contexts (prophylaxis against drug-induced liver injury) and poorly in others (viral hepatitis, cirrhosis mortality). This page reports both rather than curating the favourable half. A separate and important pharmacological thread is Silybum’s use as an intravenous antidote for Amanita phalloides (death cap) poisoning, where silibinin has genuine standing. Commercial source: Silybum marianum seed extract standardized to 80% silymarin is the industry standard; silybin-specific grades are separately available for formulators requiring the dominant single flavonolignan.

---

Evidence for Silymarin Applications

An honest account must begin with the negative findings, because they are substantial. An updated systematic review with meta-analysis of the clinical evidence for silymarin, restricted to the 19 of 65 identified papers that met double- or single-blind criteria, concluded that clinical evidence of a therapeutic effect in toxic liver diseases is scarce, and that there is no evidence of a favourable influence on the evolution of viral hepatitis, particularly hepatitis C; in liver cirrhosis, mostly alcoholic, total mortality was 16.1% with silymarin versus 20.5% with placebo — a difference that was not statistically significant (Saller 2008). In alcoholic liver disease, AST was reduced versus placebo, but alkaline phosphatase was not. Claim strength: Emerging to Moderate (indication-dependent).

The strongest positive signal is in a specific and clinically meaningful niche: prophylaxis against drug-induced liver injury. A meta-analysis of five randomized controlled trials comprising 1,198 patients (585 on silymarin, 613 on placebo) found that silymarin significantly reduced the occurrence of antituberculosis drug-induced liver injury at week 4 (risk ratio 0.33), and exerted a protective effect on liver function with significant reductions in ALT, AST, and ALP, with adverse events similar to placebo (Tao 2019). A risk ratio of 0.33 is a substantial protective effect, and the prophylactic framing — protecting a healthy liver against an incoming toxin — may be where this compound genuinely belongs. Claim strength: Moderate.

The pattern across the literature is interpretable rather than merely contradictory, and the interpretation matters commercially. Silymarin performs best as a prophylactic agent — given before or alongside a known hepatotoxic insult — and worst as a therapeutic agent in established chronic liver disease, where it has repeatedly failed to alter viral load, transaminases, or mortality. This distinction is mechanistically coherent: the proposed mechanisms (membrane stabilisation, radical scavenging, and competitive inhibition of toxin uptake at the hepatocyte membrane) are all better suited to preventing damage than reversing established fibrosis. Claim strength: Moderate.

Bioavailability is the central technical limitation and largely explains the ceiling on oral efficacy. Silymarin’s flavonolignans are poorly water-soluble, poorly absorbed, and subject to extensive first-pass metabolism and rapid biliary excretion as conjugates. This has driven the development of silybin-phosphatidylcholine complexes (phytosomes), which materially increase systemic exposure. The practical consequence is standard for this index but especially acute here: a nominal silymarin dose is not comparable across products with different delivery technologies. Claim strength: High (established pharmacokinetics).

A compositional point that carries into specification: silybin (silibinin) is the dominant and most-studied flavonolignan, comprising a large fraction of the complex and existing as two diastereomers, silybin A and B, in roughly equal proportion. The remaining constituents — isosilybin, silychristin, silydianin — differ in activity and in some assays are less potent. This means a "silymarin 80%" figure reports the summed complex without disclosing its internal composition, and two 80% extracts can differ meaningfully in silybin content. Formulators reproducing a specific trial’s material should request the flavonolignan breakdown. Claim strength: Moderate.

---

Dosage & Formulator Specification

Herbuno carries Silybum marianum seed extract standardized to 80% silymarin — the industry-standard grade — alongside a 30% silybin-standardized grade for formulators whose specification rests on the dominant flavonolignan specifically, plus unstandardized milk thistle extract in organic powder, water-soluble, and oil-soluble formats. The distinct silybin monograph in this index covers the single molecule; this page covers the complex.

Clinical dosing across the trial literature has commonly used silymarin in the range of roughly 140–420 mg/day in divided doses, with the anti-TB DILI prophylaxis trials generally at the higher end and sustained through the period of hepatotoxic drug exposure. The prophylactic framing has a direct dosing implication: the evidence supports beginning administration before or concurrently with the hepatotoxic insult rather than after damage is established, which is a materially different use pattern from open-ended "liver support" supplementation.

Analytical verification should specify silymarin content by HPLC with the individual flavonolignan breakdown — silybin A and B, isosilybin A and B, silychristin, silydianin — rather than accepting a summed figure, since two nominally identical 80% extracts can differ substantially in silybin fraction. Note that older spectrophotometric assay methods systematically overstate silymarin content relative to HPLC, and a supplier quoting a high figure should be asked which method produced it. Delivery format (standard extract versus phospholipid complex) must be specified, as it is determinative of systemic exposure.

Silymarin is one of the better-tolerated compounds in this index, with the anti-TB meta-analysis finding adverse events comparable to placebo and mild gastrointestinal effects (bloating, loose stools) being the most common complaints. Two notes. Milk thistle is an Asteraceae species, so cross-sensitivity caution for individuals with known ragweed or daisy-family allergy is appropriate. And silymarin has been reported to inhibit certain CYP and UGT enzymes in vitro; while clinically significant interactions have not been consistently demonstrated at typical doses, standard caution alongside narrow-therapeutic-index medication remains reasonable, particularly given that this ingredient is disproportionately used by people with existing hepatic compromise.

---

Frequently Asked Questions — Silymarin

Does silymarin actually protect the liver?
It depends entirely on the indication, and the honest answer is mixed. A systematic review found no favourable effect on viral hepatitis and no significant mortality benefit in cirrhosis. But a meta-analysis of five RCTs found it significantly reduced antituberculosis drug-induced liver injury (risk ratio 0.33). It performs well as prophylaxis against an incoming toxin, poorly as therapy for established disease.

Is silymarin the same as silybin?
No. Silymarin is a flavonolignan complex, not a single molecule — principally silybin A and B, isosilybin, silychristin, and silydianin, plus taxifolin. Silybin is the dominant and most-studied single constituent within it. A "silymarin 80%" figure reports the summed complex without disclosing its internal composition.

Why is silymarin bioavailability a problem?
The flavonolignans are poorly water-soluble, poorly absorbed, and undergo extensive first-pass metabolism with rapid biliary excretion as conjugates. This is why silybin-phosphatidylcholine (phytosome) complexes were developed. A nominal silymarin dose is not comparable across products using different delivery technologies.

When should silymarin be taken to be useful?
The evidence pattern favours prophylaxis over treatment. The strongest data comes from giving it before or alongside a known hepatotoxic exposure — as in the antituberculosis drug trials — rather than after liver damage is established. That is a meaningfully different use pattern from open-ended "liver support" supplementation.

Related compounds: Silybin, Silychristin, Quercetin, Kutkin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery